Crestor vs Lisinopril: Are They Interchangeable, and Can You Switch Between Them?

Why Comparing Crestor and Lisinopril Is the Wrong Frame

Crestor and lisinopril belong to entirely different drug classes and act on different physiological pathways. Asking whether one is "better" than the other is like asking whether a seatbelt is better than an airbag. Each addresses a separate risk. The question that actually matters clinically is whether a patient needs one, the other, or both.

Different Mechanisms, Different Targets

Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. That leads to upregulation of LDL receptors in the liver, a drop in circulating LDL-C by 45 to 55% at the 20 mg dose, and a modest reduction in high-sensitivity C-reactive protein (hsCRP) [1]. Lisinopril blocks angiotensin-converting enzyme, which prevents the conversion of angiotensin I to angiotensin II. The downstream effects include vasodilation, reduced aldosterone secretion, and lower systemic vascular resistance, all of which translate to lower blood pressure and reduced cardiac afterload [2].

What Each Drug Is FDA-Approved to Treat

Rosuvastatin carries FDA approval for primary and secondary prevention of cardiovascular events, reduction of LDL-C in heterozygous and homozygous familial hypercholesterolaemia, and slowing of atherosclerosis progression [3]. Lisinopril is FDA-approved for hypertension, heart failure (as adjunctive therapy), and acute myocardial infarction to improve survival [4]. The approved indications do not overlap.

When Both Are Prescribed Together

A patient with type 2 diabetes, a systolic blood pressure of 148 mmHg, and an LDL-C of 112 mg/dL might be started on both drugs at the same visit. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease explicitly supports concurrent statin and antihypertensive therapy in patients whose 10-year ASCVD risk exceeds 10% [5]. That co-prescription is not an accident. It reflects the additive and largely independent mechanisms of the two drug classes.

The Evidence Behind Rosuvastatin (Crestor)

The strongest evidence for rosuvastatin comes from the JUPITER trial, published in the New England Journal of Medicine in 2008.

JUPITER Trial Design and Results

JUPITER enrolled 17,802 adults who had LDL-C below 130 mg/dL but hsCRP of 2.0 mg/L or higher. Participants were randomised to rosuvastatin 20 mg daily or placebo and followed for a median of 1.9 years before the trial was stopped early for benefit. Rosuvastatin reduced the primary composite endpoint (MI, stroke, arterial revascularisation, hospitalisation for unstable angina, or cardiovascular death) by 44% (hazard ratio 0.56, 95% CI 0.46 to 0.69, P<0.00001) [1]. LDL-C fell by 50% and hsCRP fell by 37% in the active group.

What JUPITER Did Not Show

JUPITER was stopped early, which tends to exaggerate treatment effects. The absolute risk reduction was 1.2 events per 100 person-years, meaning the number needed to treat to prevent one primary event over the median follow-up was approximately 95. That is still clinically meaningful for a once-daily generic tablet, but the relative risk figures headline-writers prefer can mislead patients who expect near-certain protection.

High-Intensity Statin Dosing

The 2018 ACC/AHA Guideline on the Management of Blood Cholesterol categorises rosuvastatin 20 to 40 mg as high-intensity statin therapy, expected to lower LDL-C by 50% or more [6]. Patients with established ASCVD who are on rosuvastatin 40 mg and still above their LDL-C target may need ezetimibe or a PCSK9 inhibitor added, not a drug-class switch.

Rosuvastatin Safety Profile

Muscle-related adverse effects (myalgia, myopathy) occur in roughly 5 to 10% of statin users in observational studies, though the rate in randomised trials is lower [7]. Rhabdomyolysis is rare, estimated at fewer than 1 per 10,000 patient-years at standard doses [7]. The FDA label for rosuvastatin notes a dose-dependent increase in new-onset diabetes, consistent across statins as a class [3]. Creatine kinase (CK) and liver enzyme monitoring is recommended when symptoms arise, not routinely.

The Evidence Behind Lisinopril

ALLHAT Trial Design and Results

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) randomised 33,357 high-risk hypertensive patients aged 55 or older to chlorthalidone, amlodipine, or lisinopril. The primary outcome was fatal coronary heart disease or nonfatal MI. At 4.9 years of follow-up, lisinopril showed no statistically significant difference from chlorthalidone in the primary outcome (relative risk 1.00, 95% CI 0.90 to 1.11) [8]. However, the stroke rate in the lisinopril arm was 15% higher than in the chlorthalidone arm (relative risk 1.15, 95% CI 1.02 to 1.30), a finding that influenced subsequent guideline positioning of ACE inhibitors relative to thiazide diuretics for stroke prevention.

Where Lisinopril Excels

ACE inhibitors including lisinopril reduce proteinuria and slow the progression of diabetic nephropathy. A meta-analysis of 43 trials (N=17,110) published in the Lancet found that ACE inhibitors reduced the risk of end-stage renal disease by 31% compared with placebo in patients with diabetic kidney disease [9]. For a patient with hypertension and microalbuminuria, lisinopril offers organ protection that rosuvastatin does not.

Lisinopril in Heart Failure

The ATLAS trial compared low-dose (2.5 to 5 mg) and high-dose (32.5 to 35 mg) lisinopril in 3,164 patients with heart failure and found that high-dose therapy reduced the combined risk of death or hospitalisation by 12% (P=0.002) [10]. The 2022 AHA/ACC/HFSA Heart Failure Guideline gives ACE inhibitors a Class I recommendation for patients with heart failure with reduced ejection fraction (HFrEF) [11].

Lisinopril Safety Profile

The most common adverse effect is a dry cough, reported in 5 to 35% of patients (higher rates in patients of East Asian ancestry) [4]. Angioedema occurs in approximately 0.1 to 0.7% of patients and is a contraindication to rechallenge with any ACE inhibitor [4]. Lisinopril is absolutely contraindicated in pregnancy (FDA Pregnancy Category D; can cause fetal renal dysgenesis and oligohydramnios) [4]. Hyperkalemia and acute kidney injury are risks in patients with pre-existing renal impairment or concurrent use of potassium-sparing diuretics.

Direct Comparison: Rosuvastatin vs Lisinopril Across Key Dimensions

No randomised head-to-head trial has compared rosuvastatin with lisinopril, because prescribing one instead of the other is almost never the clinical decision being made. The table below synthesises data from separate trials and FDA labelling.

| Dimension | Rosuvastatin (Crestor) | Lisinopril | |---|---|---| | Drug class | Statin (HMG-CoA reductase inhibitor) | ACE inhibitor | | Primary indication | Dyslipidaemia, ASCVD prevention | Hypertension, HFrEF, post-MI | | LDL-C reduction | 45 to 55% at 20 mg [1] | Minimal direct effect | | SBP reduction | Mild (5 to 10 mmHg in some studies) [12] | 10 to 15 mmHg typical at 10 to 40 mg [8] | | Kidney protection | Not a primary mechanism | Yes, especially in diabetic nephropathy [9] | | Heart failure | Not indicated | Class I for HFrEF [11] | | Pregnancy safety | Contraindicated | Contraindicated | | Common adverse effects | Myalgia, new-onset diabetes | Dry cough, hyperkalemia | | Serious adverse effects | Rhabdomyolysis (<1/10,000 py) | Angioedema (0.1 to 0.7%) | | Generic cost (US) | Approximately $10, $25/month | Approximately $4, $10/month |

Can You Switch From Crestor to Lisinopril (or Vice Versa)?

Direct substitution is almost never clinically appropriate. The two drugs solve different problems.

When a Switch Might Seem Tempting (and Why It Usually Fails)

A patient with high LDL-C AND high blood pressure who cannot tolerate rosuvastatin might ask whether lisinopril can "cover" the cardiovascular risk instead. It cannot. Lisinopril does not meaningfully lower LDL-C. The mechanisms of atherosclerosis driven by hyperlipidaemia versus those driven by hypertension overlap but are not interchangeable. Dropping a statin in favour of an antihypertensive leaves LDL-driven plaque progression unaddressed.

When Adding the Second Drug Is the Right Move

If a patient is already on rosuvastatin and develops hypertension, the answer is to add lisinopril, not to stop rosuvastatin. The ACC/AHA 2019 primary prevention guideline supports this combination explicitly [5]. Conversely, a patient already on lisinopril who has an elevated 10-year ASCVD risk should be evaluated for statin initiation, not offered a lisinopril dose increase as a substitute.

The One Scenario Where a Transition Touches Both Drugs

Post-MI patients are often started on both a high-intensity statin and an ACE inhibitor simultaneously, per the 2021 ACC Expert Consensus Decision Pathway for Optimizing Heart Failure Treatment [13]. In that context, the clinician is not choosing between the drugs. Both are started, and the question becomes dose optimisation over subsequent weeks. Lisinopril is typically up-titrated to the maximum tolerated dose over 6 to 8 weeks; rosuvastatin is often fixed at 40 mg from discharge.

The HealthRX cardiometabolic prescribing team uses a three-question triage before recommending a medication change in patients already on one of these drugs:

1. What is the patient's primary uncontrolled risk factor right now (LDL-C, blood pressure, or both)?
2. Is the request to switch driven by intolerance, cost, or a misconception about drug interchangeability?
3. If intolerance is the driver, is there a within-class alternative before crossing drug classes?

This framework prevents unnecessary gaps in LDL or blood pressure control during transitions.

Statin Intolerance: What to Do Instead of Switching to an ACE Inhibitor

If a patient cannot tolerate rosuvastatin because of myalgia, the answer is a within-class substitution or a dose reduction, not a switch to lisinopril.

Alternative Statins and Non-Statin Options

Pravastatin 40 mg and fluvastatin 80 mg are generally considered lower in myopathy risk because of reduced CYP3A4 metabolism [14]. The SAMSON trial (N=60) used an n-of-1 crossover design and found that approximately 90% of statin-associated muscle symptoms were not attributable to pharmacological statin exposure when controlling for nocebo effects [15]. That finding supports a re-challenge protocol before abandoning statin therapy entirely.

If a true statin intolerance exists, ezetimibe 10 mg daily lowers LDL-C by approximately 18 to 20% as monotherapy [16]. PCSK9 inhibitors (evolocumab, alirocumab) achieve LDL-C reductions of 50 to 60% and carry a Class I recommendation for patients with ASCVD who cannot tolerate statins [6]. None of these alternatives are lisinopril.

ACE Inhibitor Intolerance: Within-Class and Cross-Class Options

If a patient cannot tolerate lisinopril because of cough, the standard substitution is an angiotensin receptor blocker (ARB) such as losartan or valsartan [4]. ARBs provide equivalent blood pressure and renal protection with a substantially lower cough rate (approximately 3% vs up to 35% for ACE inhibitors) [17]. Switching to rosuvastatin would leave blood pressure uncontrolled.

Monitoring Parameters After Starting Either Drug

Rosuvastatin Monitoring

A fasting lipid panel should be checked 4 to 12 weeks after starting rosuvastatin to confirm LDL-C response, then every 3 to 12 months [6]. CK is not routinely measured but should be checked if the patient reports muscle pain, weakness, or dark urine. Liver enzyme testing is indicated if hepatic symptoms arise; routine baseline testing is no longer required by the FDA label [3].

Lisinopril Monitoring

Serum potassium and serum creatinine should be checked within 1 to 2 weeks of starting lisinopril, particularly in patients with diabetes, chronic kidney disease, or concurrent NSAID use [4]. A rise in creatinine of up to 30% from baseline is considered acceptable and may reflect improved glomerular haemodynamics rather than injury [18]. Blood pressure should be rechecked at 2 to 4 weeks after initiation or any dose change.

Drug Interactions Worth Knowing

Rosuvastatin is minimally metabolised by CYP3A4 and is instead a substrate for OATP1B1/OATP1B3 transporters. Ciclosporin raises rosuvastatin plasma levels significantly; the FDA label caps rosuvastatin at 5 mg daily in patients on ciclosporin [3]. Fibrates, particularly gemfibrozil, increase the risk of myopathy when combined with any statin [14].

Lisinopril combined with potassium-sparing diuretics (spironolactone, eplerenone) raises the risk of clinically significant hyperkalemia, defined as serum potassium above 5.5 mEq/L [4]. NSAIDs blunt the antihypertensive effect of lisinopril and may precipitate acute kidney injury in volume-depleted patients [4]. Neither drug has a clinically significant pharmacokinetic interaction with the other, which is one reason co-prescription is straightforward.

Cost and Access Considerations

Generic rosuvastatin became widely available in the United States after 2016. At major pharmacy chains with discount programs, a 30-day supply of rosuvastatin 20 mg runs approximately $10, $25 without insurance. Lisinopril has been generic since the early 2000s and is available for approximately $4, $10 per month on the major discount programs such as GoodRx [19]. Both drugs are on most insurance formularies at Tier 1 or Tier 2. Cost is rarely the reason to choose one over the other; the reason is always the clinical indication.